Resource Logo
NLM AIDSLINE

Safety and immunogenicity of HIV-1 Tat toxoid in immunocompromised HIV-1-infected patients [see comments]




 

J Hum Virol. 1998 May-Jun;1(4):293-8. Unique Identifier : AIDSLINE

OBJECTIVES: To antagonize the deleterious effects of the HIV-1 toxin extracellular Tat on uninfected immune cells, we developed a new strategy of anti-HIV-1 vaccine using an inactivated but immunogenic Tat (Tat toxoid). Tat toxoid has been assayed for safety and immunogenicity in seropositive patients. METHOD: The phase I vaccine clinical trial testing Tat toxoid preparation in Seppic Isa 51 oil adjuvant was performed on 14 HIV-1-infected asymptomatic although biologically immunocompromised individuals (500-200 CD4+ cells/mm3). RESULTS: Following as many as 8 injections, no clinical defects were observed. All patients exhibited an antibody (Ab) response to Tat, and some had cell-mediated immunity (CMI) as evaluated by skin test in vivo and T-cell proliferation in vitro. CONCLUSION: These results provide initial evidence of safety and potency of Tat toxoid vaccination in HIV-1-infected individuals.

CLINICAL TRIAL CLINICAL TRIAL, PHASE I JOURNAL ARTICLE Acquired Immunodeficiency Syndrome/*IMMUNOLOGY/THERAPY/VIROLOGY Adult AIDS Vaccines/ADVERSE EFFECTS/*IMMUNOLOGY/THERAPEUTIC USE Comparative Study CD4 Lymphocyte Count Disease Progression Female Follow-Up Studies Gene Products, tat/ADVERSE EFFECTS/*IMMUNOLOGY/THERAPEUTIC USE Human HIV Antibodies/IMMUNOLOGY HIV Core Protein p24/IMMUNOLOGY HIV-1/*CHEMISTRY/IMMUNOLOGY Immunocompromised Host Male Pilot Projects



 




Information in this article was accurate in July 30, 1999. The state of the art may have changed since the publication date. This material is designed to support, not replace, the relationship that exists between you and your doctor. Always discuss treatment options with a doctor who specializes in treating HIV.